PACS Company Profile and Key Details

Short-term trend indicators are bearishly aligned (SMA20 9.11%, SMA50 9.87%, SMA200 109.18%). The stock’s 14-day RSI is 62.13 (firm momentum), while the ATR of 2.06 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -3.27% below its high and over 455.6% above its low. Average 10-day trading volume of 697.65 thousand shares is below the 3-month average of 856.29 thousand, indicating normal recent market interest.

Wall Street analysts project EPS growth of 11.69% annually over the next five years. Analyst sentiment is bullish. Analyst rating data shows there are 6 Strong Buy ratings, 4 Buy ratings, 0 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $58.00 to $33.00. The high target offers 30.19% upside. The low target suggests -25.93% downside. The mean target is $48.00. This offers 7.74% upside. PACS Group, Inc. earnings surprise history is a mixed track record. The quarter that ended August 04, 2026, missed forecasts by 17.32%. The prior quarter beat by 49.05%. Over the last six quarters, Apple has recorded several small beats. These include -114.89% in August 25, 2025.

PACS Group, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $33.72. This means the shares are trading above this model’s fair value.

PACS Group, Inc. (NYSE:PACS) closed at $44.55 USD, losing -$0.21 (-0.47%) from the previous close of $44.76. The stock is currently mid-range between its 52-week high and low $9.69 and $49.49. With a market capitalization of about $7.05 billion, PACS Group, Inc. is classified as a mid-cap and shows lower-than-market volatility (beta ~-0.08). Key stats such as the average daily volume over the past year has been around 861.40 thousand shares, in line with its 52-week average. Headquartered in Salt Lake City, UT, PACS Group, Inc. operates in the Healthcare sector and the Medical - Care Facilities industry. Led by CEO Jason Murray, the company employs approximately 47,455 people and listed since April 11, 2024. PACS Group, Inc. operates as a holding company, primarily focused on delivering post-acute healthcare services.

PACS Group, Inc. has 158.34 million shares outstanding. The public float is 48.12 million shares, elevated short interest at 7.91% of float. This equals 3.82 million shares. The short ratio is 4.19 days. Institutional investors hold 101.11% of the float. Insiders own 69.53%. Murray Jason Hulse holds 54.57 million shares, Hancock Mark has 53.91 million shares and Jergensen Joshua has 2.54 million shares. Over the past six months, insider transactions show net selling. They sold 722.65 thousand shares across 32 transactions.

PACS Group, Inc. trades at a P/E ratio of 26.4, slightly below the S&P 500 average, with a price-to-sales ratio of 1.28 and a price-to-book ratio of 6.39 trading at moderately above to book value. The P/FCF stands at 15.59, also above market averages.

PACS Group, Inc. (NYSE:PACS) shares are flat -7.03% year-to-date currently trading near 52-week highs band. Short-term momentum has been positive over the last quarter, despite recent volatility. Valuation shows PACS Group, Inc. trading at a premium to the broader market with a P/E of 26.4. Analyst sentiment is bullish, with the majority of ratings in Overweight territory and a mean price target of $41.68, suggesting -6.44% downside. Our AI forecast model points to short-term weakness (-1.21% over two weeks), a medium-term rise (103.23% over three months), and a longer-term gain (21.46% over one year), with expected trading ranges indicating moderate volatility.

Our AI price prediction model suggests that PACS Group, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected decline of -1.21%, with price expected at $44.01 by September 25, 2026, within a range of $42.80 to $45.21 3-Month Outlook: Projected rise of 103.23%, reaching $90.54 by December 10, 2026, with a range of $89.83 to $91.16. 1-Year Outlook: Projected gain of 21.46%, with price at $54.11 by September 10, 2027, within a range of $50.54 to $59.67.